Loading patent…
AssigneeBoehringer Ingelheim International GmbH
InventorsChristian HESSLINGER, Verena BAUER, Sebastian Martin BOSSERT, Susan KOBER, Yi LIU, Peter NICKOLAUS, Maria SARNO, Florian VOSS
Estimating the term…
The invention concerns an oral pharmaceutical composition consisting essentially of the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and optionally of one or more pharmaceutically acceptable carriers or excipients for use in the treatment of a patient suffering from one or more progressive fibrosing interstitial lung diseases (PF-ILD), wherein this oral pharmaceutical composition is to be administered to the patient twice daily. The invention further concerns oral pharmaceutical compositions comprising the PDE4B-inhibitor of formula III in the dose of 18 mg or 9 mg and a therapeutically effective dose of a second active ingredient selected from nintedanib or pirfenidone, wherein these oral pharmaceutical compositions are administered to the patient twice daily.
A method of treating a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD) comprising the step of administering to said patient twice daily 18 mg of the PDE4B-inhibitor of formula III
(canceled)
Method of treating a patient suffering from a progressive fibrosing interstitial lung disease (PF-ILD) comprising the step of administering to said patient twice daily an oral pharmaceutical composition consisting essentially of 18 mg of the PDE4B-inhibitor of formula III
(canceled)
A method of treating a patient suffering from idiopathic pulmonary fibrosis (IPF) comprising the step of administering to said patient twice daily 18 mg of the PDE4B-inhibitor of formula III
Method of treating a patient suffering from idiopathic pulmonary fibrosis (IPF) comprising the step of administering to said patient twice daily an oral pharmaceutical composition consisting essentially of 18 mg of the PDE4B-inhibitor of formula III
Dependencies are inferred from the claim text.